Company intelligence / Profile preview

Anhui Aike'er Pharmaceutical

Hefei, Anhui, China

Ownership: Private
Development stage: Other

Overview

Anhui Aike'er Pharmaceutical is a China-based biotechnology company focused on the research and development of innovative small molecule drugs for metabolic diseases. The company primarily targets chronic conditions such as type 2 diabetes and obesity, with a pipeline featuring GLP-1 receptor agonists and DPP-4 inhibitors. Anhui Aike'er operates out of the Anhui province, leveraging local R&D infrastructure to advance its candidates through clinical trials. Its lead programs aim to provide effective oral and injectable therapeutic options for the growing metabolic health market in China.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Anhui Aike'er Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anhui Aike'er Pharmaceutical.

Explore the full profile